Epidermal growth factor receptor inhibitor PKI-166 governs cardiovascular protection without beneficial effects on the kidney in hypertensive 5/6 nephrectomized ratss

Journal of Pharmacology and Experimental Therapeutics

Volumn 345, Issue 3, 2013, Pages 393-403

  Ulu, Nadir ^a   Mulder, Gemma M ^a   Vavrinec, Peter ^a   Landheer, Sjoerd W ^a   Duman Dalkilic, Basak ^b   Gurdal, Hakan ^b   Goris, Maaike ^a   Duin, Marry ^a   Van Dokkum, Richard P E ^a   Buikema, Hendrik ^a   Van Goor, Harry ^a   Henning, Robert H ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b ANKARA UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; ANGIOTENSIN II; LISINOPRIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL REACTIVITY; CONTROLLED STUDY; CREATININE CLEARANCE; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; HEART PROTECTION; HYPERTENSION; KIDNEY INJURY; MALE; MESENTERIC ARTERY; NEPHRECTOMY; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; RAT; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; URINE VOLUME; VASOCONSTRICTION;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; AORTA, THORACIC; BLOOD PRESSURE; CARDIOTONIC AGENTS; HYPERTENSION, RENAL; IMMUNOHISTOCHEMISTRY; KIDNEY; LISINOPRIL; MALE; MESENTERIC ARTERIES; MUSCLE CONTRACTION; MUSCLE TONUS; MUSCLE, SMOOTH, VASCULAR; NEPHRECTOMY; PROTEINURIA; PYRIMIDINES; PYRROLES; RATS; RATS, WISTAR; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, ADRENERGIC, ALPHA-1;

EID: 84878104605     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.113.203497     Document Type: Article

References (57)

1. Advani A, Wiggins KJ, Cox AJ, Zhang Y, Gilbert RE, and Kelly DJ (2011) Inhibition of the epidermal growth factor receptor preserves podocytes and attenuates albuminuria in experimental diabetic nephropathy. Nephrology (Carlton) 16:573-581.
2. Amann K, Kronenberg G, Gehlen F, Wessels S, Orth S, Münter K, Ehmke H, Mall G, and Ritz E (1998) Cardiac remodelling in experimental renal failure-an immunohistochemical study. Nephrol Dial Transplant 13:1958-1966.
3. Asakura M, Kitakaze M, Takashima S, Liao Y, Ishikura F, Yoshinaka T, Ohmoto H, Node K, Yoshino K, and Ishiguro H, et al. (2002) Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: Metalloproteinase inhibitors as a new therapy. Nat Med 8:35-40.
4. Bakris GL, Williams M, Dworkin L, Elliott WJ, Epstein M, Toto R, Tuttle K, Douglas J, Hsueh W, and Sowers J; National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group (2000) Preserving renal function in adults with hypertension and diabetes: A consensus approach. Am J Kidney Dis 36: 646-661.
5. Bella JN, Palmieri V, Roman MJ, Liu JE, Welty TK, Lee ET, Fabsitz RR, Howard BV, and Devereux RB (2002) Mitral ratio of peak early to late diastolic filling velocity as a predictor of mortality in middle-aged and elderly adults: The Strong Heart Study. Circulation 105:1928-1933.
6. Beltowski J and Lowicka E (2009) EGF receptor as a drug target in arterial hypertension. Mini Rev Med Chem 9:526-538.
7. Benter IF, Canatan H, Benboubetra M, Yousif MH, and Akhtar S (2009) Global upregulation of gene expression associated with renal dysfunction in DOCA-saltinduced hypertensive rats occurs via signaling cascades involving epidermal growth factor receptor: A microarray analysis. Vascul Pharmacol 51:101-109.
8. Boffa JJ, Tharaux PL, Placier S, Ardaillou R, Dussaule JC, and Chatziantoniou C (1999) Angiotensin II activates collagen type I gene in the renal vasculature of transgenic mice during inhibition of nitric oxide synthesis: Evidence for an endothelin-mediated mechanism. Circulation 100:1901-1908.
9. Chatziantoniou C, Boffa JJ, Ardaillou R, and Dussaule JC (1998) Nitric oxide inhibition induces early activation of type I collagen gene in renal resistance vessels and glomeruli in transgenic mice. Role of endothelin. J Clin Invest 101:2780-2789.
10. Chen J, Chen JK, Neilson EG, and Harris RC (2006) Role of EGF receptor activation in angiotensin II-induced renal epithelial cell hypertrophy. J Am Soc Nephrol 17: 1615-1623.
11. Dorrance AM, Osborn HL, Grekin R, and Webb RC (2001) Spironolactone reduces cerebral infarct size and EGF-receptor mRNA in stroke-prone rats. Am J Physiol Regul Integr Comp Physiol 281:R944-R950.
12. Fernandez-Patron C (2007) Therapeutic potential of the epidermal growth factor receptor transactivation in hypertension: A convergent signaling pathway of vascular tone, oxidative stress, and hypertrophic growth downstream of vasoactive Gprotein-coupled receptors? Can J Physiol Pharmacol 85:97-104.
13. Florian JA and Watts SW (1999) Epidermal growth factor: A potent vasoconstrictor in experimental hypertension. Am J Physiol 276:H976-H983.
14. Fortuño A, San José G, Moreno MU, Díez J, and Zalba G (2005) Oxidative stress and vascular remodelling. Exp Physiol 90:457-462.
15. François H, Placier S, Flamant M, Tharaux PL, Chansel D, Dussaule JC, and Chatziantoniou C (2004) Prevention of renal vascular and glomerular fibrosis by epidermal growth factor receptor inhibition. FASEB J 18:926-928.
16. Fujino T, Hasebe N, Fujita M, Takeuchi K, Kawabe J, Tobise K, Higashiyama S, Taniguchi N, and Kikuchi K (1998) Enhanced expression of heparin-binding EGFlike growth factor and its receptor in hypertrophied left ventricle of spontaneously hypertensive rats. Cardiovasc Res 38:365-374.
17. Ghosh SS, Krieg RJ, Sica DA, Wang R, Fakhry I, and Gehr T (2009) Cardiac hypertrophy in neonatal nephrectomized rats: The role of the sympathetic nervous system. Pediatr Nephrol 24:367-377.
18. Gilbert RE, Kelly DJ, McKay T, Chadban S, Hill PA, Cooper ME, Atkins RC, and Nikolic-Paterson DJ (2001) PDGF signal transduction inhibition ameliorates experimental mesangial proliferative glomerulonephritis. Kidney Int 59: 1324-1332.
19. Gretz N (1995) The development of hypertension in the remnant kidney model after either pole resection or partial infarction of the kidney. J Am Soc Nephrol 5: 1839-1840.
20. Griendling KK, Sorescu D, and Ushio-Fukai M (2000) NAD(P)H oxidase: Role in cardiovascular biology and disease. Circ Res 86:494-501.
21. Griol-Charhbili V, Fassot C, Messaoudi S, Perret C, Agrapart V, and Jaisser F (2011) Epidermal growth factor receptor mediates the vascular dysfunction but not the remodeling induced by aldosterone/salt. Hypertension 57:238-244.
22. Grossman W, Jones D, and McLaurin LP (1975) Wall stress and patterns of hypertrophy in the human left ventricle. J Clin Invest 56:56-64.
23. Gschwend S, Pinto-Sietsma SJ, Buikema H, Pinto YM, van Gilst WH, Schulz A, de Zeeuw D, and Kreutz R (2002) Impaired coronary endothelial function in a rat model of spontaneous albuminuria. Kidney Int 62:181-191.
24. Harker CT, O'Donnell MP, Kasiske BL, Keane WF, and Katz SA (1993) The reninangiotensin system in the type II diabetic obese Zucker rat. J Am Soc Nephrol 4: 1354-1361.
25. Hoekstra R, Dumez H, Eskens FA, van der Gaast A, Planting AS, de Heus G, Sizer KC, Ravera C, Vaidyanathan S, and Bucana C, et al. (2005) Phase I and pharmacologic study of PKI166, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. Clin Cancer Res 11: 6908-6915.
26. Jaffré F, Bonnin P, Callebert J, Debbabi H, Setola V, Doly S, Monassier L, Mettauer B, Blaxall BC, and Launay JM, et al. (2009) Serotonin and angiotensin receptors in cardiac fibroblasts coregulate adrenergic-dependent cardiac hypertrophy. Circ Res 104:113-123.
27. Johnson RJ, Herrera-Acosta J, Schreiner GF, and Rodriguez-Iturbe B (2002) Subtle acquired renal injury as a mechanism of salt-sensitive hypertension. N Engl J Med 346:913-923.
28. Jolma P, Kalliovalkama J, Tolvanen JP, Kööbi P, Kähönen M, Saha H, and Pörsti I (2002) Preserved endothelium-dependent but impaired beta-adrenergic relaxation of the resistance vessels in experimental renal failure. Exp Nephrol 10:348-354.
29. Judge KW, Pawitan Y, Caldwell J, Gersh BJ, and Kennedy JW (1991) Congestive heart failure symptoms in patients with preserved left ventricular systolic function: Analysis of the CASS registry. J Am Coll Cardiol 18:377-382.
30. Kagiyama S, Eguchi S, Frank GD, Inagami T, Zhang YC, and Phillips MI (2002) Angiotensin II-induced cardiac hypertrophy and hypertension are attenuated by epidermal growth factor receptor antisense. Circulation 106:909-912.
31. Kagiyama S, Qian K, Kagiyama T, and Phillips MI (2003) Antisense to epidermal growth factor receptor prevents the development of left ventricular hypertrophy. Hypertension 41:824-829.
32. Kennedy D, Omran E, Periyasamy SM, Nadoor J, Priyadarshi A, Willey JC, Malhotra D, Xie Z, and Shapiro JI (2003) Effect of chronic renal failure on cardiac contractile function, calcium cycling, and gene expression of proteins important for calcium homeostasis in the rat. J Am Soc Nephrol 14:90-97.
33. Klotz S, Hay I, Zhang G, Maurer M, Wang J, and Burkhoff D (2006) Development of heart failure in chronic hypertensive Dahl rats: Focus on heart failure with preserved ejection fraction. Hypertension 47:901-911.
34. Lassila M, Jandeleit-Dahm K, Seah KK, Smith CM, Calkin AC, Allen TJ, and Cooper ME (2005) Imatinib attenuates diabetic nephropathy in apolipoprotein E-knockout mice. J Am Soc Nephrol 16:363-373.
35. Lautrette A, Li S, Alili R, Sunnarborg SW, Burtin M, Lee DC, Friedlander G, and Terzi F (2005) Angiotensin II and EGF receptor cross-talk in chronic kidney diseases: A new therapeutic approach. Nat Med 11:867-874.
36. Liang HY, Cauduro SA, Pellikka PA, Bailey KR, Grossardt BR, Yang EH, Rihal C, Seward JB, Miller FA, and Abraham TP (2006) Comparison of usefulness of echocardiographic Doppler variables to left ventricular end-diastolic pressure in predicting future heart failure events. Am J Cardiol 97:866-871.
37. Maurer MS, Spevack D, Burkhoff D, and Kronzon I (2004) Diastolic dysfunction: Can it be diagnosed by Doppler echocardiography? J Am Coll Cardiol 44:1543-1549.
38. Meggs LG, Ben-Ari J, Gammon D, Choudhury M, and Goodman AI (1986) Effect of chronic uremia on the cardiovascular alpha 1 receptor. Life Sci 39:169-179.
39. Mulder GM, Nijboer WN, Seelen MA, SandoviciM, Bos EM, Melenhorst WB, TrzpisM, Kloosterhuis NJ, Visser L, and Henning RH, et al. (2010) Heparin binding epidermal growth factor in renal ischaemia/reperfusion injury. J Pathol 221:183-192.
40. Nakano S, Kobayashi N, Yoshida K, Ohno T, and Matsuoka H (2005) Cardioprotective mechanisms of spironolactone associated with the angiotensinconverting enzyme/epidermal growth factor receptor/extracellular signalregulated kinases, NAD(P)H oxidase/lectin-like oxidized low-density lipoprotein receptor-1, and Rho-kinase pathways in aldosterone/salt-induced hypertensive rats. Hypertens Res 28:925-936.
41. Northcott C, Florian JA, Dorrance A, and Watts SW (2001) Arterial epidermal growth factor receptor expression in deoxycorticosterone acetate-salt hypertension. Hypertension 38:1337-1341.
42. Ohtsu H, Dempsey PJ, Frank GD, Brailoiu E, Higuchi S, Suzuki H, Nakashima H, Eguchi K, and Eguchi S (2006) ADAM17 mediates epidermal growth factor receptor transactivation and vascular smooth muscle cell hypertrophy induced by angiotensin II. Arterioscler Thromb Vasc Biol 26:e133-e137.
43. Parfrey PS and Foley RN (1999) The clinical epidemiology of cardiac disease in chronic renal failure. J Am Soc Nephrol 10:1606-1615.
44. Portik-Dobos V, Harris AK, Song W, Hutchinson J, Johnson MH, Imig JD, Pollock DM, and Ergul A (2006) Endothelin antagonism prevents early EGFR transactivation but not increased matrix metalloproteinase activity in diabetes. Am J Physiol Regul Integr Comp Physiol 290:R435-R441.
45. Rump LC, Amann K, Orth S, and Ritz E (2000) Sympathetic overactivity in renal disease: A window to understand progression and cardiovascular complications of uraemia? Nephrol Dial Transplant 15:1735-1738.
46. Schellings MW, Baumann M, van Leeuwen RE, Duisters RF, Janssen SH, Schroen B, Peutz-Kootstra CJ, Heymans S, and Pinto YM (2006) Imatinib attenuates endorgan damage in hypertensive homozygous TGR(mRen2)27 rats. Hypertension 47: 467-474.
47. Swaminathan N, Vincent M, Sassard J, and Sambhi MP (1996) Elevated epidermal growth factor receptor levels in hypertensive Lyon rat kidney and aorta. Clin Exp Pharmacol Physiol 23:793-796.
48. Uchiyama-Tanaka Y, Matsubara H, Nozawa Y, Murasawa S, Mori Y, Kosaki A, Maruyama K, Masaki H, Shibasaki Y, and Fujiyama S, et al. (2001) Angiotensin II signaling and HB-EGF shedding via metalloproteinase in glomerular mesangial cells. Kidney Int 60:2153-2163.
49. Ulu N, Gurdal H, Landheer SW, Duin M, Guc MO, Buikema H, and Henning RH (2010) a1-Adrenoceptor-mediated contraction of rat aorta is partly mediated via transactivation of the epidermal growth factor receptor. Br J Pharmacol 161: 1301-1310.
50. Ulu N, Schoemaker RG, Henning RH, Buikema H, Teerlink T, Zijlstra FJ, Bakker SJ, van Gilst WH, and Navis G (2009) Proteinuria-associated endothelial dysfunction is strain dependent. Am J Nephrol 30:209-217.
51. Van Dokkum RP, Alonso-Galicia M, Provoost AP, Jacob HJ, and Roman RJ (1999) Impaired autoregulation of renal blood flow in the fawn-hooded rat. Am J Physiol 276:R189-R196.
52. Vettoretti S, Ochodnicky P, Buikema H, Henning RH, Kluppel CA, de Zeeuw D, and van Dokkum RP (2006) Altered myogenic constriction and endotheliumderived hyperpolarizing factor-mediated relaxation in small mesenteric arteries of hypertensive subtotally nephrectomized rats. J Hypertens 24:2215-2223.
53. Wassef L, Kelly DJ, and Gilbert RE (2004) Epidermal growth factor receptor inhibition attenuates early kidney enlargement in experimental diabetes. Kidney Int 66:1805-1814.
54. Windt WA, Henning RH, Kluppel AC, Xu Y, de Zeeuw D, and van Dokkum RP (2008a) Myocardial infarction does not further impair renal damage in 5/6 nephrectomized rats. Nephrol Dial Transplant 23:3103-3110.
55. Windt WA, van Dokkum RP, Kluppel CA, Jeronimus-Stratingh CM, Hut F, de Zeeuw D, and Henning RH (2008b) Therapeutic resistance to angiotensin converting enzyme (ACE) inhibition is related to pharmacodynamic and-kinetic factors in 5/6 nephrectomized rats. Eur J Pharmacol 580:231-240.
56. Xu Y, Henning RH, Sandovici M, van der Want JJ, van Gilst WH, and Buikema H (2009) Enhanced myogenic constriction of mesenteric artery in heart failure relates to decreased smooth muscle cell caveolae numbers and altered AT1-and epidermal growth factor-receptor function. Eur J Heart Fail 11:246-255.
57. Zile MR, Gaasch WH, Carroll JD, Feldman MD, Aurigemma GP, Schaer GL, Ghali JK, and Liebson PR (2001) Heart failure with a normal ejection fraction: Is measurement of diastolic function necessary to make the diagnosis of diastolic heart failure? Circulation 104:779-782.